Sharechat Logo

AFT Pharmaceuticals Limited (NZX: AFT) AFT welcomes Australian Federal Court appeal success

Thursday 9th December 2021

Text too small?

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today welcomes the Australian Federal Court’s decision this week to allow its appeal of a comparative advertising judgement brought by Reckitt Benckiser.

The Australian Federal Court has found AFT was justified in making a series of claims in relation to the efficacy of its Maxigesic pain relief tablets in comparison to Ibuprofen alone or paracetamol alone.

Reckitt Benckiser has until 4 January 2022 to file an application for special leave to appeal to the High Court should it so chose. We are therefore unable to make further comment at this time.

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website

Please see the link below for details

AFT welcomes Australian Federal Court appeal success

Source: AFT Pharmaceuticals Limited

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

4th July 2022 Morning Report
BIF - Acquires shares in Hot Lime Labs
RUA - Cann Group granted TGA GMP for Mildura facility
AFI - Invitation to Results Webcast
PFI Share Buyback Programme to Pause
Greenfern Industries Limited ("GFI") - Late Annual Report
FSF - Monthly Allotment/ Redemption Notice
1st July 2022 Morning Report
General Capital Releases 2022 Annual Report
Fonterra, NZX, EEX confirm GDT strategic partnership